Quantcast

Latest Sunitinib Stories

2011-07-08 00:19:00

EAST HANOVER, N.J., July 8, 2011 /PRNewswire/ -- Novartis Pharmaceuticals Corporation ("Novartis") announced today Phase III trial results that showed more than one-third of patients taking Afinitor® (everolimus) tablets* experienced a 50% or greater reduction in the size of their subependymal giant cell astrocytomas (SEGAs), non-cancerous brain tumors associated with tuberous sclerosis complex (TSC)(1,2,6). This study, the largest prospective clinical trial to date...

2011-07-01 06:54:20

(Ivanhoe Newswire) "“ A new study reveals that cancer patients treated with the drugs sunitinib and sorafenib responded to the flu vaccine, which suggests the agents do not damage the immune system as much as previously feared. "The damage that chemotherapy does to normal, healthy cells as it treats cancer has been well documented, but the precise effect that the new class of targeted agents has on the immune system is less well known. This study helps us answer that question," Keith...

2011-06-29 12:12:54

Patients treated with sunitinib and sorafenib responded to the flu vaccine, which suggests the agents do not damage the immune system as much as previously feared, according to a study in Clinical Cancer Research, a journal of the American Association for Cancer Research. Keith Flaherty, M.D., director of developmental therapeutics at the Massachusetts General Hospital and a senior editor of Clinical Cancer Research, said the findings have broad implications beyond questions of patient...

2011-06-21 13:50:00

ATLANTA, June 21, 2011 /PRNewswire/ -- MDOUTLOOK®, the global oncology intelligence initiative powered by The Arcas Group, announced results from 4th Annual Quick Poll research launched immediately following this month's annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago. These Quick Polls expand on previous Quick Polls carried out after the past 3 ASCO annual meetings, as well as similar efforts after the American Society of Hematology (ASH)...

2011-06-15 02:00:00

TUEBINGEN, Germany, June 15, 2011 /PRNewswire/ -- igoommatics biotechnologies GmbH, a biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, announced today that the first patients have been vaccinated in the IMPRINT study, a pivotal Phase III trial with IMA901, the company's lead cancer vaccine for the treatment of renal cell carcinoma (RCC). The trial is designed to demonstrate the overall survival benefit of IMA901 in...

2011-06-05 10:00:00

DURHAM, N.C., June 5, 2011 /PRNewswire/ -- Argos Therapeutics today announced that new data from its Phase 2 combination study of its Arcelis(TM) immunotherapy for the treatment of renal cell carcinoma (RCC), AGS-003, in combination with sunitinib showed improvement over expectations for sunitinib alone in progression-free survival (PFS) in newly diagnosed metastatic RCC patients with unfavorable prognosis. Induction of anti-tumor (CD28+) memory T cell responses correlated with PFS and...

2011-06-03 13:30:48

Results from Phase 2 study at University Hospitals Case Medical Center, UCSF and Columbia In data presented at The American Society of Clinical Oncology (ASCO) Annual Meeting, cancer researchers found that the brain tumor vaccine HSPPC-96 for treating recurrent gliobastoma (GBM) has a favorable safety profile and extends survival by two to three times more than the current median survival rate. Patients in the study, conducted at University Hospitals Case Medical Center, University of...

2011-06-01 07:00:00

DURHAM, N.C., June 1, 2011 /PRNewswire/ -- Argos Therapeutics announced today that its Arcelis(TM) immunotherapy for the treatment of renal cell carcinoma (RCC), AGS-003, in combination with sunitinib demonstrated a strong immunologic response that correlated to improved clinical outcomes. The Phase 2 combination study in newly diagnosed, metastatic RCC patients with unfavorable prognosis demonstrated decreases in T regulatory cells, along with a concurrent expansion of CD28+memory...

2011-06-01 00:24:00

EAST HANOVER, N.J., June 1, 2011 /PRNewswire/ -- Novartis Pharmaceuticals Corporation ("Novartis") will showcase data from 140 abstracts on its current oncology products and investigational agents at the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO). These data underscore the company's commitment to developing treatments to improve the lives of patients with cancer. "Through our commitment to R&D and collaborations with the scientific and patient communities,...

2011-05-20 17:14:00

MANHATTAN BEACH, Calif., May 20, 2011 /PRNewswire/ -- The Pfizer drug Sutent® (sunitinib) has been approved for the treatment of advanced pancreatic neuroendocrine tumors by the U.S. Food and Drug Administration (FDA). Sutent® is the second targeted drug to be approved this month for the treatment of pancreatic neuroendocrine tumors, which make up less than five percent of all pancreatic cancer diagnoses and are generally slower growing and less...


Word of the Day
tesla
  • The unit of magnetic flux density in the International System of Units, equal to the magnitude of the magnetic field vector necessary to produce a force of one newton on a charge of one coulomb moving perpendicular to the direction of the magnetic field vector with a velocity of one meter per second. It is equivalent to one weber per square meter.
This word is named for Nikola Tesla, the inventor, engineer, and futurist.